Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Authors

Martin Wermke, Technical University Dresden
Enriqueta Felip, Vall d'Hebron University Hospital
Valentina Gambardella, University of Valencia
Yasutoshi Kuboki, National Cancer Center Hospital East
Daniel Morgensztern, Washington University School of Medicine in St. Louis
Zohra Oum' Hamed, Boehringer Ingelheim France S.A.S.
Meiruo Liu, Boehringer Ingelheim Pharmaceuticals Inc
Matus Studeny, Boehringer Ingelheim International GmbH
Taofeek K Owonikoko, University of Pittsburgh

Journal

Future Oncology

Publication Date

8-1-2022

Volume

18

Issue

24

First Page

2639

Last Page

2649

Document Type

Open Access Publication

DOI

10.2217/fon-2022-0196

Rights and Permissions

Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed ZO, Liu M, Studeny M, Owonikoko TK. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncol. 2022 Aug;18(24):2639-2649. doi: 10.2217/fon-2022-0196. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. Standard citation, plus DOI, CC license; and this statement: For full bibliographic citation, please refer to the version available at www.futuremedicine.com.

Recommended Citation

Wermke, Martin; Felip, Enriqueta; Gambardella, Valentina; Kuboki, Yasutoshi; Morgensztern, Daniel; Hamed, Zohra Oum'; Liu, Meiruo; Studeny, Matus; and Owonikoko, Taofeek K, "Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas." Future Oncology. 18, 24. 2639 - 2649. (2022).
https://digitalcommons.wustl.edu/oa_4/407